South Korea · Delayed Price · Currency is KRW Prestige BioPharma Company Description
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, antibody drugs, and vaccines in Singapore.
The company offers Trastuzumab biosimilar for the treatment of breast cancer; Bevacizumab biosimilar for the treatment in oncology; and PBP1502, an adalimumab biosimilar, which is in Phase 1 clinical trial for the treatment in immunity.
It also develops PBP1510, a first-in-class antibody, which is in phase 1/2a clinical trial for the treatment of pancreatic cancer; PBP1710, a first-in-class antibody that is in preclinical trials for the treatment of solid tumor and fibrosis; and IDC007, a bispecific antibody for the treatment of CRS.
In addition, the company is developing IDC005, IDC001, IDC002, IDC003, IDC008, and IDC009 bispecific antibodies; IDC111, a first-in-class antibody; IDC112, first-in-class antibody; IDC113 first-in-class antibody; IDC332, IDC331, IDC333, and IDC334 novel concept antibodies; and IDC441, an ADC antibody for the treatment of solid tumours.
Additionally, it offers biosimilars for immunology, endocrinology, oncology, haematology, and dermatology diseases.
Further, it develops IDC221, a PAUF-based pancreatic cancer diagnostic solution for the treatment of pancreatic cancers.
Prestige BioPharma Limited was incorporated in 2015 and is headquartered in Singapore.
| Country | Singapore |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 54 |
| CEO | So-Yeon Park |
Contact Details
Address: #04-24 Nucleos South Building Singapore, 138567 Singapore | |
| Phone | 65 6924 6535 |
| Website | prestigebiopharma.com |
Stock Details
| Ticker Symbol | 950210 |
| Exchange | Korea Stock Exchange |
| Fiscal Year | July - June |
| Reporting Currency | KRW |
| ISIN Number | KR8702070002 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| So-Yeon Park | Chairman and Chief Executive Officer |
| Jinwoo Kim | Vice Chairman of the Board and Chief Financial Officer |
| Dong -Jo Shin | Head of Finance |
| Michael Ruppert | Head of Business Development |
| Neil O'Connor | CMCB Head |
| Sumita Pradhan | R&MA Head |
| Sumiko Shiba | Secretary |
| Kay K.H. Lee | Clinical Development Manager |
| Ghislain M.C Bonamy | General Manager of Licensing |